Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Table 8

Factor of antibody titer increase over natural infection titers for each age group by oncogenic HPV type for Cervarix [69–72].

	10–15 years old [72]		15–25 years old [70, 71]		26–45 years old [71]		46–55 years old [71]
	HPV 16	HPV 18	HPV 16	HPV 18	HPV 16	HPV 18	HPV 16	HPV 18
Month 7	253	170	107	82	230	91	84	57
Month 24	40	25	22	26	28	12	16	8
Month 48	29	18	20	15	18	8	11	5
Seroconversion at 48 months: % (95% CI)	100% (98, 100)	100% (98, 100)	100% (98, 100)	100% (98, 100)	100% (97, 100)	100% (98, 100)	100% (97, 100)	99.4% (97, 100)

Population is according to protocol, which included females seronegative to HPV 16/18 at baseline who received all three doses of study vaccine or placebo according to schedule, complied with the blood sampling schedule, and did not become positive for HPV-16/18-DNA during the trial.
Seropositivity at 48 months among women seronegative for HPV 16/18 at baseline, who received Cervarix in the ATP cohort. Seropositivity is defined as antibody titers ≥8 ELU/mL for HPV 16; ≥7 ELU/mL for HPV-18. Measured by type-specific ELISA testing.